Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 231-912-9 | CAS number: 7778-74-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The oral route is the most likely route of (repeated) exposure.
A NOAEL value is not determined by the study reliable enough to be used as starting point for the derivation of a DNEL. Thus the LOAEL value is used as a starting point.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.3100 (90-Day Oral Toxicity in Rodents)
- GLP compliance:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Details on species / strain selection:
- The test animals were obtained from Charles River Laboratories, Inc., Kingston, NY, USA
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- 12 h light/ 12 h darc cycle; 22 +- 2 °C, 50 +- 15% relative humidity, 12 - 15 air changes/h; 2 weeks of acclimation time
- Route of administration:
- oral: drinking water
- Vehicle:
- water
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- validated ion chromatography method
- Duration of treatment / exposure:
- 14 and 90 days, respectively
- Dose / conc.:
- 0.01 mg/kg bw/day (nominal)
- Remarks:
- Group 2
- Dose / conc.:
- 0.05 mg/kg bw/day (nominal)
- Remarks:
- Group 3
- Dose / conc.:
- 0.2 mg/kg bw/day (nominal)
- Remarks:
- Group 4
- Dose / conc.:
- 1 mg/kg bw/day (nominal)
- Remarks:
- Group 5
- Dose / conc.:
- 10 mg/kg bw/day (nominal)
- Remarks:
- Group 6
- No. of animals per sex per dose:
- 20 or 30, respectively
- Control animals:
- yes
- Details on study design:
- For each dose group and the control group at least 20 male and 20 female animals were used. At day 14 and day 90, respectively, 10 male and 10 female animals of each group were euthanized and necropsied. In the groups 1, 3, 5 and 6 10 additional animals of each sex were euthanized after a 90-day period of treatment followed by a 30-day period of recovery.
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- On all test animals the following examinations and analysis were conducted:
- ophthalmology prior to study initiation
- body weights, weight gain, food and water consumption
- clinical pathology and TSH, T3 and T4 analyses
- estrous cycling or sperm analysis, respectively
- gross necropsy and histopathology
- micronucleus formation - Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, non-treatment-related
- Food consumption and compound intake (if feeding study):
- effects observed, non-treatment-related
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- effects observed, non-treatment-related
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- effects observed, non-treatment-related
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- The absolute thyroid weights increased in the group 6 (dose of 10.0 mg/kg/day).
- Gross pathological findings:
- not specified
- Neuropathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- The non-neoplastic thyroid histopathological effects are summarizes in the table.
- Histopathological findings: neoplastic:
- no effects observed
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- histopathology: non-neoplastic
- Key result
- Dose descriptor:
- LOAEL
- Effect level:
- 10 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: thyroid effects
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 10 mg/kg bw/day (actual dose received)
- System:
- endocrine system
- Organ:
- thyroid gland
- Treatment related:
- yes
- Dose response relationship:
- not specified
- Relevant for humans:
- yes
- Conclusions:
- The NOAEL for ammonium perchlorate was determined to be 1.00 mg /kg bw/d.
The NOAEL for potassium perchlorate is 1.18 mg /kg bw/d. - Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Justification for type of information:
- In water, potassium perchlorate will rapidly dissolve and completely dissociate into the perchlorate anion and the corresponding cation. Toxicity is determined only by the perchlorate moiety of the salt. as potassium is known to be non-toxic. Based on that, read-across is possible to other perchlorate salt dissociating in water without any toxic cation.
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across: supporting information
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.3100 (90-Day Oral Toxicity in Rodents)
- GLP compliance:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Details on species / strain selection:
- The test animals were obtained from Charles River Laboratories, Inc., Kingston, NY, USA
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- 12 h light/ 12 h darc cycle; 22 +- 2 °C, 50 +- 15% relative humidity, 12 - 15 air changes/h; 2 weeks of acclimation time
- Route of administration:
- oral: drinking water
- Vehicle:
- water
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- validated ion chromatography method
- Duration of treatment / exposure:
- 14 and 90 days, respectively
- Dose / conc.:
- 0.01 mg/kg bw/day (nominal)
- Remarks:
- Group 2
- Dose / conc.:
- 0.05 mg/kg bw/day (nominal)
- Remarks:
- Group 3
- Dose / conc.:
- 0.2 mg/kg bw/day (nominal)
- Remarks:
- Group 4
- Dose / conc.:
- 1 mg/kg bw/day (nominal)
- Remarks:
- Group 5
- Dose / conc.:
- 10 mg/kg bw/day (nominal)
- Remarks:
- Group 6
- No. of animals per sex per dose:
- 20 or 30, respectively
- Control animals:
- yes
- Details on study design:
- For each dose group and the control group at least 20 male and 20 female animals were used. At day 14 and day 90, respectively, 10 male and 10 female animals of each group were euthanized and necropsied. In the groups 1, 3, 5 and 6 10 additional animals of each sex were euthanized after a 90-day period of treatment followed by a 30-day period of recovery.
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- On all test animals the following examinations and analysis were conducted:
- ophthalmology prior to study initiation
- body weights, weight gain, food and water consumption
- clinical pathology and TSH, T3 and T4 analyses
- estrous cycling or sperm analysis, respectively
- gross necropsy and histopathology
- micronucleus formation - Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, non-treatment-related
- Food consumption and compound intake (if feeding study):
- effects observed, non-treatment-related
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- effects observed, non-treatment-related
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- effects observed, non-treatment-related
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- The absolute thyroid weights increased in the group 6 (dose of 10.0 mg/kg/day).
- Gross pathological findings:
- not specified
- Neuropathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- The non-neoplastic thyroid histopathological effects are summarizes in the table.
- Histopathological findings: neoplastic:
- no effects observed
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1.18 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- histopathology: non-neoplastic
- Remarks on result:
- other: potassium perchlorate equivalents
- Key result
- Dose descriptor:
- LOAEL
- Effect level:
- 11.8 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: thyroid effects
- Remarks on result:
- other: potassium perchlorate equivalents
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 10 mg/kg bw/day (actual dose received)
- System:
- endocrine system
- Organ:
- thyroid gland
- Treatment related:
- yes
- Dose response relationship:
- not specified
- Relevant for humans:
- yes
- Conclusions:
- The NOAEL for ammonium perchlorate was determined to be 1.00 mg /kg bw/d.
The NOAEL for potassium perchlorate is 1.18 mg /kg bw/d. - Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- supporting study
- Reliability:
- 3 (not reliable)
- Rationale for reliability incl. deficiencies:
- data from handbook or collection of data
- Reason / purpose for cross-reference:
- read-across source
- Specific details on test material used for the study:
- Review on several perchlorate salts. Due to the dissociating behaviour of soluble perchlorates the toxicity is only caused by the perchlorat moiety as potassium is known not to be toxic.
- Dose descriptor:
- LOEL
- Effect level:
- >= 35 other: mg/d
- Based on:
- other: perchlorate anion
- Sex:
- not specified
- Conclusions:
- The review summarizes existing studies on human oral uptake of perchlorate salts. It is summarized that in most publicated studies an effect on humans can be observed at an uptake of 35 mg potassium per day or more.
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- The methodes described are similar to OECD 408. Some minor deviations have no impact on the reliability of the study.
- Deviations:
- yes
- Remarks:
- The methodes described are similar to OECD 408. Some minor deviations have no impact on the reliability of the study.
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.3100 (90-Day Oral Toxicity in Rodents)
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- The test animals were obtained from Charles River Laboratories (Raleigh, NC) and acclimated for 11 days. Animals were 6 - 7 weeks old at the date of study inition, weighed 195 - 197 g (males) and 151 - 153 g (females), respectively. The animals were housed in induvidual cages. Diet: PMI Certified Rodent Chow, ad libitum was given. Water: reverse osmosis water, ad libitum was given. The 90-day treatment period was followed by a 30 day recovery period.
Environmental conditions: 18 - 26 °C, 30 - 70 % humidity, 10 - 15 air changes per hour, 12 h light / 12 h dark photo period - Route of administration:
- oral: drinking water
- Vehicle:
- water
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The perchlorate concentrations were determined by ion chromatography.
- Duration of treatment / exposure:
- satellite groups: 14 days
main study group: 90 days - Frequency of treatment:
- continous during application period
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Remarks:
- control group
- Dose / conc.:
- 0.01 mg/kg bw/day (nominal)
- Dose / conc.:
- 0.05 mg/kg bw/day (nominal)
- Dose / conc.:
- 0.2 mg/kg bw/day (nominal)
- Dose / conc.:
- 1 mg/kg bw/day (nominal)
- Dose / conc.:
- 10 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 10 male + 10 female
- Control animals:
- yes, concurrent vehicle
- Positive control:
- for micronucleus interpretation (additional animals treated with cyclophosphamide)
- Observations and examinations performed and frequency:
- daily: mortality; weekly: body weight, food consumption, water consumption
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- effects observed, treatment-related
- Neuropathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- effects observed, treatment-related
- Description (incidence and severity):
- Hormonal effects were observed due to changes in T3 and T4 (decrease) and TSH (increase). All observed hormonal effects were reversible.
- Key result
- Dose descriptor:
- LOEL
- Effect level:
- 10 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- organ weights and organ / body weight ratios
- other: changes in T3, T4 and TSH levels
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no exposure-related effect observed at this concentration
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 10 mg/kg bw/day (nominal)
- System:
- endocrine system
- Organ:
- thyroid gland
- Treatment related:
- yes
- Dose response relationship:
- not specified
- Relevant for humans:
- yes
- Conclusions:
- No toxicologically meaningful differences were observed between the control and perchlorate-treated groups with respect to survival, clinical observations, body weights, food consumption, water consumption, ophthalmology, hematology, clinical chemistry, estrous cycling, sperm parameters, or bone marrow micronucleus formation. A target organ effect was produced by AP in the thyroids of male and female rats at the 10 mg/kg/day level after 14 and 90 days of exposure. The effect was characterized by significantly increased thyroid weights and thyroid histopathology consisting primarily of follicular cell hypertrophy with microfollicle formation and colloid depletion. These changes were reversible after a nontreatment recovery period of 30 days. Statistically significant changes in TSH and thyroid hormones were observed at all ammonium perchlorate dosage levels tested; however, no thyroid organ weight or histopathological effects were observed at AP dosage levels < or = 1.0 mg/kg/day.
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Justification for type of information:
- In water, potassium perchlorate will rapidly dissolve and completely dissociate into the perchlorate anion and the corresponding cation. Toxicity is determined only by the perchlorate moiety of the salt. as potassium is known to be non-toxic. Based on that, read-across is possible to other perchlorate salt dissociating in water without any toxic cation.
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across: supporting information
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- The methodes described are similar to OECD 408. Some minor deviations have no impact on the reliability of the study.
- Deviations:
- yes
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.3100 (90-Day Oral Toxicity in Rodents)
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- The test animals were obtained from Charles River Laboratories (Raleigh, NC) and acclimated for 11 days. Animals were 6 - 7 weeks old at the date of study inition, weighed 195 - 197 g (males) and 151 - 153 g (females), respectively. The animals were housed in induvidual cages. Diet: PMI Certified Rodent Chow, ad libitum was given. Water: reverse osmosis water, ad libitum was given. The 90-day treatment period was followed by a 30 day recovery period.
Environmental conditions: 18 - 26 °C, 30 - 70 % humidity, 10 - 15 air changes per hour, 12 h light / 12 h dark photo period - Route of administration:
- oral: drinking water
- Vehicle:
- water
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The perchlorate concentrations were determined by ion chromatography.
- Duration of treatment / exposure:
- satellite groups: 14 days
main study group: 90 days - Frequency of treatment:
- continous during application period
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Remarks:
- control group
- Dose / conc.:
- 0.01 mg/kg bw/day (nominal)
- Dose / conc.:
- 0.05 mg/kg bw/day (nominal)
- Dose / conc.:
- 0.2 mg/kg bw/day (nominal)
- Dose / conc.:
- 1 mg/kg bw/day (nominal)
- Dose / conc.:
- 10 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 10 male + 10 female
- Control animals:
- yes, concurrent vehicle
- Positive control:
- for micronucleus interpretation (additional animals treated with cyclophosphamide)
- Observations and examinations performed and frequency:
- daily: mortality; weekly: body weight, food consumption, water consumption
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- effects observed, treatment-related
- Neuropathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- effects observed, treatment-related
- Description (incidence and severity):
- Hormonal effects were observed due to changes in T3 and T4 (decrease) and TSH (increase). All observed hormonal effects were reversible.
- Key result
- Dose descriptor:
- LOEL
- Effect level:
- 11.8 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- organ weights and organ / body weight ratios
- other: changes in T3, T4 and TSH levels
- Remarks on result:
- other: potassium perchlorate equivalents
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1.18 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no exposure-related effect observed at this concentration
- Remarks on result:
- other: potassium perchlorate equivalents
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 10 mg/kg bw/day (nominal)
- System:
- endocrine system
- Organ:
- thyroid gland
- Treatment related:
- yes
- Dose response relationship:
- not specified
- Relevant for humans:
- yes
- Conclusions:
- No toxicologically meaningful differences were observed between the control and perchlorate-treated groups with respect to survival, clinical observations, body weights, food consumption, water consumption, ophthalmology, hematology, clinical chemistry, estrous cycling, sperm parameters, or bone marrow micronucleus formation. A target organ effect was produced by AP in the thyroids of male and female rats at the 10 mg/kg/day level after 14 and 90 days of exposure. The effect was characterized by significantly increased thyroid weights and thyroid histopathology consisting primarily of follicular cell hypertrophy with microfollicle formation and colloid depletion. These changes were reversible after a nontreatment recovery period of 30 days. Statistically significant changes in TSH and thyroid hormones were observed at all ammonium perchlorate dosage levels tested; however, no thyroid organ weight or histopathological effects were observed at AP dosage levels < or = 1.0 mg/kg/day.
The NOAEL for ammonium perchlorate was determined to be 1.00 mg /kg bw/d.
The NOAEL for potassium perchlorate is 1.18 mg /kg bw/d.
The LOEL for ammonium perchlorate was determined to be 10.0 mg /kg bw/d.
The LOEL for potassium perchlorate is 11.8 mg /kg bw/d.
Referenceopen allclose all
The non-neoplastic thyroid histopathological effects are summarizes in the table.
total incidences | Group 1 (0 mg/kg/day) | Group 2 (0.01 mg/kg/day) | Group 3 (0.05 mg/kg/day) | Group 4 (0.2 mg/kg/day) | Group 5 (1.0 mg/kg/day) | Group 6 (10.0 mg/kg/day) |
14-day interval, males | 1/8 | 0/10 | 1/10 | 0/10 | 0/10 | 10/10 |
14 -day interval, females | 0/10 | 0/10 | 0/10 | 0/10 | 0/10 | 7/10 |
90-day interval, males | 2/10 | 0/10 | 0/10 | 0/10 | 1/10 | 8/10 |
90-day interval, females | 0/10 | 0/10 | 0/10 | 0/10 | 0/10 | 9/10 |
The non-neoplastic thyroid histopathological effects are summarizes in the table.
total incidences | Group 1 (0 mg/kg/day) | Group 2 (0.01 mg/kg/day) | Group 3 (0.05 mg/kg/day) | Group 4 (0.2 mg/kg/day) | Group 5 (1.0 mg/kg/day) | Group 6 (10.0 mg/kg/day) |
14-day interval, males | 1/8 | 0/10 | 1/10 | 0/10 | 0/10 | 10/10 |
14 -day interval, females | 0/10 | 0/10 | 0/10 | 0/10 | 0/10 | 7/10 |
90-day interval, males | 2/10 | 0/10 | 0/10 | 0/10 | 1/10 | 8/10 |
90-day interval, females | 0/10 | 0/10 | 0/10 | 0/10 | 0/10 | 9/10 |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LOAEL
- 11.8 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
- System:
- endocrine system
- Organ:
- thyroid gland
Additional information
Justification for classification or non-classification
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.